向SPAK抑制了进展,并避免了肝细胞癌的免疫消耗性微环境
Yonglong Pan1,2,3,4, Chenglong Zeng1,2,3, Yi He1,2,3
1Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Nature communications
|January 12, 2026
概括
与STE20/SPS1相关的林/氨酸丰富激酶 (SPAK) 驱动肝细胞癌 (HCC) 的进展和免疫衰竭. 抑制SPAK和PD-1阻断显示出对HCC治疗的希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 蛋白激酶与肝细胞癌 (HCC) 的发展和免疫逃避有关.
- 由于这些因素,有效管理HCC仍然是一个重大挑战.
研究的目的:
- 在HCC中确定新的治疗点.
- 研究与STE20/SPS1相关的氨酸/氨酸丰富激酶 (SPAK) 在HCC进展和免疫衰竭中的作用.
主要方法:
- 聚合选蛋白激酶以确定候选基因.
- 生物信息分析和患者队列数据集成.
- 在小鼠模型和细胞系中进行功能研究.
主要成果:
- 升高的SPAK表达促进HCC的进展,增强干性,并驱动免疫疲劳.
- 通过酸化GSK3β,抑制c-Jun和PD-L1降解,SPAK有助于抵抗向疗法.
- DNMT3B依赖的SPAK甲基化增加了其在HCC中的表达.
结论:
- 在HCC中,SPAK是瘤发生和免疫衰竭的关键驱动因素.
- 针对SPAK,特别是与PD-1封锁相结合,代表了对HCC的有希望的治疗策略.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
07:25Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
7.3K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K